- Report
- August 2025
- 188 Pages
Global
From €3483EUR$3,939USD£3,007GBP
- Report
- August 2025
- 194 Pages
Global
From €3483EUR$3,939USD£3,007GBP
- Report
- August 2025
- 195 Pages
Global
From €3134EUR$3,545USD£2,706GBP
€3483EUR$3,939USD£3,007GBP
- Report
- April 2025
- 200 Pages
Global
From €3970EUR$4,490USD£3,427GBP
- Report
- April 2025
- 200 Pages
Global
From €3970EUR$4,490USD£3,427GBP
- Report
- May 2024
- 130 Pages
United States
From €5261EUR$5,950USD£4,542GBP
- Report
- May 2024
- 200 Pages
Global
From €3669EUR$4,150USD£3,168GBP
- Report
- August 2025
- 50 Pages
Global
From €2343EUR$2,650USD£2,023GBP
Indium-111 (In-111) is a radioactive isotope of indium used in nuclear medicine and radiopharmacology. It is used in a variety of imaging procedures, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). In-111 is also used in targeted radiotherapy, where it is bound to a monoclonal antibody or other targeting agent and used to deliver radiation to a specific area of the body. In-111 has a relatively short half-life of 2.8 days, which makes it ideal for use in nuclear medicine.
The Indium-111 market is composed of a variety of companies that produce and distribute the isotope. These include Nordion, a Canadian-based company that produces and distributes radiopharmaceuticals; IBA Molecular, a French-based company that produces and distributes radiopharmaceuticals; and Eckert & Ziegler, a German-based company that produces and distributes radiopharmaceuticals. Other companies in the market include Jubilant DraxImage, Lantheus Medical Imaging, and Bracco Diagnostics. Show Less Read more